Dapaflozin 10 mg, Sitagliptin 100 mg & Metformin SR 500 mg "

Dapaflozin 10 mg, Sitagliptin 100 mg & Metformin SR 500 mg
GLIDAPA 3D 10/100/500 SR  

GLIDAPA 3D 10/100/500 SR is a combination medication widely used in the management of type 2 diabetes mellitus. This innovative formula combines Dapagliflozin (10 mg), Sitagliptin (100 mg), and Metformin SR (500 mg) to target multiple pathways involved in blood glucose regulation. By addressing insulin resistance, glucose absorption, and renal glucose reabsorption, GLIDAPA 3D provides an effective approach to controlling blood sugar levels in patients with type 2 diabetes.

Composition

GLIDAPA 3D 10/100/500 SR contains the following active ingredients:

1. Dapagliflozin (10 mg)
   • A sodium-glucose co-transporter-2 (SGLT2) inhibitor.
2. Sitagliptin (100 mg)
   • A dipeptidyl peptidase-4 (DPP-4) inhibitor.
3. Metformin SR (500 mg)
   • A biguanide that acts primarily by reducing liver glucose production.

Mechanism of Action

The unique combination of these three active ingredients works synergistically to manage blood glucose levels. Each drug in GLIDAPA 3D plays a distinct role in diabetes management:

1. Dapagliflozin
   Dapagliflozin inhibits the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, reducing the reabsorption of glucose back into the bloodstream. This leads to increased glucose excretion through urine, thereby lowering blood glucose levels. By acting on the kidneys, dapagliflozin provides a complementary action to other diabetic medications, reducing overall blood sugar.

2. Sitagliptin
   Sitagliptin inhibits the DPP-4 enzyme, which inactivates incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory peptide). These hormones increase insulin secretion and decrease glucagon production in a glucose-dependent manner. By prolonging the action of incretin hormones, sitagliptin enhances insulin secretion and helps regulate blood sugar levels after meals.

3. Metformin SR (Sustained Release)
   Metformin reduces hepatic glucose production by inhibiting gluconeogenesis in the liver. It also enhances insulin sensitivity in peripheral tissues, facilitating better uptake of glucose by muscles. The sustained-release formulation of Metformin in GLIDAPA 3D ensures a gradual and prolonged effect, minimizing gastrointestinal side effects commonly associated with immediate-release Metformin formulations.

Indications

GLIDAPA 3D is primarily prescribed for the management of type 2 diabetes mellitus in adults. It is particularly beneficial for patients who:

• Have poor blood glucose control despite lifestyle modifications.
• Require multiple agents for blood glucose control.
• Are unable to achieve adequate glycemic control with monotherapy.

It may be used as an adjunct to diet and exercise or in combination with other diabetic medications when required.

Dosage and Administration

• Initial Dose: The usual starting dose of GLIDAPA 3D is one tablet daily, taken orally with or after food, to reduce gastrointestinal discomfort.
• Adjustments: The dose may be adjusted based on blood glucose levels and the patient’s response to treatment.
• Maximum Dose: The maximum recommended dose is one tablet per day, unless otherwise directed by a healthcare provider.

Patients should follow their healthcare provider's instructions on dosage and timing. It is important to monitor blood glucose regularly to assess the effectiveness of the medication.

Side Effects

While GLIDAPA 3D is generally well tolerated, some patients may experience side effects:

1. Common Side Effects:

   • Gastrointestinal Issues: Nausea, diarrhea, abdominal discomfort, and flatulence, particularly with Metformin.
   • Urinary Tract Infections (UTIs): Dapagliflozin may increase the risk of UTIs due to increased glucose in urine.
   • Headache, dizziness: These may occur, especially when starting treatment.

2. Serious Side Effects:

   • Lactic Acidosis: A rare but serious condition that can occur with Metformin. Symptoms include muscle pain, breathing difficulties, and fatigue.
   • Pancreatitis: Sitagliptin has been associated with an increased risk of pancreatitis.
   • Dehydration & Electrolyte Imbalance: Dapagliflozin can lead to dehydration, especially in patients with renal impairment.
   • Genital Infections: Due to the glucosuria induced by Dapagliflozin, there may be a risk of fungal or bacterial infections, particularly in women.
   • Hypoglycemia: When used with other antidiabetic drugs like sulfonylureas or insulin, there is an increased risk of hypoglycemia.

Drug Interactions

GLIDAPA 3D may interact with other medications, including:

• Diuretics: Increased risk of dehydration and hypotension.
• Corticosteroids and Hormones: Can affect blood glucose levels.
• ACE inhibitors: May increase the risk of hyperkalemia and renal impairment when used with Dapagliflozin.
• Insulin and Sulfonylureas: Increased risk of hypoglycemia when combined with these drugs.

Conclusion

GLIDAPA 3D 10/100/500 SR is an advanced combination therapy that provides a multifaceted approach to the management of type 2 diabetes. It offers patients an effective, once-daily treatment option that targets the core mechanisms of diabetes—insulin resistance, excessive glucose production, and impaired renal glucose reabsorption. With careful monitoring and appropriate adjustments, GLIDAPA 3D can significantly improve glycemic control, reduce complications, and enhance the quality of life for individuals living with type 2 diabetes. Steris Healthcare Pvt Ltd, operating as Sterispharma since its founding by expert professionals in the pharmaceutical industry in February 2018, is based in Navi Mumbai. The company is certified by WHO, GMP, and ISO, emphasizing its commitment to quality and safety. Sterispharma focuses on providing high-quality drugs at affordable prices throughout India, adhering strictly to WHO guidelines. Offering the convenience of an online pharmacy, customers can easily purchase medicines with home delivery options available. Sterispharma's mission is to supply a broad range of healthcare products to meet the diverse needs of the medical community. From advanced treatments and medications for rare conditions to essential health necessities, Sterispharma aims to serve the extensive demands of the healthcare industry. You can order medicines from Sterispharma through their websites, Sterisonline,  Sterisindia and Sterispharma. Their extensive product lineup includes treatments for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. 

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 7877551268, 7849827488

BUY NOW